The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients
M. Mitterer et al., The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients, BR J HAEM, 106(3), 1999, pp. 737-743
The aim of this study was to determine the presence of monoclonal myeloma p
recursor B cells in peripheral blood stem cell harvests and to investigate
their role in the clinical outcome of multiple myeloma patients. A total of
39 multiple myeloma patients were treated with a sequential therapy includ
ing double high-dose melphalan therapy followed by a double transplant proc
edure. The apheresis products for the second transplant were purged using a
panel of four or five different mouse monoclonal antibodies against B-cell
antigens (CD10, CD19, CD20, CD22 and CD37, In 19/39 patients a tumour-spec
ific CDR III signal was identified in the diagnostic bone marrow Gene scan
analysis after CDR LII PCR of the magnetic bead isolated B-cell fraction fr
om the apheresis products in these 19 patients revealed three different pat
terns: 32% of patients had a predominantly monoclonal B-cell population: 63
% of patients had an identifiable monoclonal signal within an oligoclonal B
-cell population, In only 1/19 patients were no monoclonal B cells identifi
ed in the B-cell population of the apheresis product. A correlation between
the clonal pattern and the clinical response after sequential chemotherapy
was found. Patients with a predominance of monoclonal myeloma or myeloma p
recursor B cells had an early relapse or achieved a minimal response or a p
artial remission. Patients with an oligo- and/or polyclonal pattern achieve
d a high percentage of partial as well as complete remissions.